drug
(cagrilintide + semaglutide)
pre_registrationupdated 5mo agoby Novo Nordisk AS
community read0 votes
indications
indications
Obesity
all catalysts(0)
nothing on the calendar yet
Trials studying (cagrilintide + semaglutide)
- phase1A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet
- phase1A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity
- phase3A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
- phase3A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term
- phase3A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
- phase2A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes
- phase3A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight
- phase2A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
News(10)
- Superior weight loss, blood sugar control propel Lilly’s amylin-GIP/GLP-1 combo into Phase 3EloraTZP—a combination of an amylin asset and Eli Lilly’s approved obesity drug Zepbound—made a clean sweep of the primary and secondary endpoints in a mid-stage trial of adults with obesity and ty…biospace · 4d ago
- #EASD26: Lilly's amylin-Zepbound combo posts best-ever weight loss in patients with obesity and diabetesMILAN — Forget Wegovy and Zepbound. Never mind CagriSema, and even retatrutide. The latest big name in obesity is eloraTZP. Data revealed Wednesday show that Lilly's amylin-incretin combination del…endpoints · 4d ago
- Lilly raises diabetes weight-loss bar with amylin-Zepbound comboEli Lilly announced its amylin-Zepbound combination eloraTZP resulted in 23.3% weight loss in adults with type 2 diabetes and obesity or overweight, topping its own triple-G drug candidate retatrut…fiercebiotech · 4d ago
- Novo talks up drug launches in effort to win back investorsAt a “capital markets day” in London, executives outlined a roadmap to better compete with key rival Eli Lilly and soon bring forth several multibillion-dollar products.biopharma_dive · 13d ago
- Novo offers low-dose CagriSema data as approval decision loomsAs its capital markets day in London continued on Monday, Novo released data that suggested its investigational metabolic drug CagriSema was competitive with Eli Lilly’s Mounjaro when each was give…endpoints · 13d ago
- Novo’s plan to hit $23B in revenue by 2035 leaves investors wantingNovo has “gone shopping” to fill pipeline gaps, with a focus on obesity and diabetes, plus an expansion in blood and endocrine disorders, liver diseases and cardiovascular conditions.biospace · 13d ago
- Novo struggles to appease restive investors with consumer plans, blockbuster ambitionsWith reports leaking out of investor discontent, CEO Mike Doustdar opened Novo's Capital Markets Day by acknowledging that the company’s leadership “have to convince” the audience that “there is a…fiercebiotech · 13d ago
- Myriad catalysts on deck for obesity’s brightest stars as market continues to accelerateCurrent leaders Eli Lilly and Novo Nordisk have cornered the early market for weight loss therapeutics, but several other players, large and small, are bidding for a piece of the potential $200 bil…biospace · 1mo ago
- Amylin design debate heats up as Lilly's crucial mid-stage weight loss data nearIn the amylin race, drug design appears to be a key differentiator. Later this year, Novo Nordisk’s CagriSema is likely to become the first approved drug containing an amylin analog and a GLP-1 ago…endpoints · 1mo ago
- Novo takes first round of oral obesity duel. Can it stay ahead of Lilly?Despite coming away with an early victory over Eli Lilly in the oral obesity face-off, analysts don’t expect Novo Nordisk’s lead to last for very long.biospace · 1mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that